Last reviewed · How we verify
Tazarotene (Fabior™)
Tazarotene is a topical retinoid that modulates the expression of genes involved in cell proliferation and differentiation.
Tazarotene is a topical retinoid that modulates the expression of genes involved in cell proliferation and differentiation. Used for Acne vulgaris, Psoriasis.
At a glance
| Generic name | Tazarotene (Fabior™) |
|---|---|
| Sponsor | Actavis Inc. |
| Drug class | retinoid |
| Target | retinoic acid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to retinoic acid receptors, which are nuclear receptors that regulate gene expression. This leads to changes in the expression of genes involved in cell proliferation and differentiation, ultimately resulting in the reduction of acne lesions and the improvement of skin texture.
Approved indications
- Acne vulgaris
- Psoriasis
Common side effects
- Skin irritation
- Dry skin
- Redness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tazarotene (Fabior™) CI brief — competitive landscape report
- Tazarotene (Fabior™) updates RSS · CI watch RSS
- Actavis Inc. portfolio CI